PODCAST: Clinical showdowns in the second quarter

Got 10 minutes (well, 12 if we’re being precise)? Grab a cuppa and listen to our latest podcast diving into some of the big catalysts we’ll be looking out for in the second quarter.

In the latest edition of our regular podcast that looks at upcoming catalysts, it was the turn of Vantage’s deputy editor Amy Brown to join me in the podcast studio.

This quarter, it’s like a rollcall of all the key indications that have been in the spotlight in recent months and years. Alzheimer’s, obesity, RSV…there’s something coming up for all of them. One of the biggest readouts we ponder is Novo’s attempt to claim a cardiovascular benefit with its obesity juggernaut Wegovy. Of course, we cover some of the latest in oncology too, including the thresholds that Immunogen needs to meet with its confirmatory Mirasol study. 

It’s all wrapped up in a quick chat between me and Amy, so grab your headphones and listen in. You’ll also find all the stories we reference conveniently below as well. Enjoy!

Our catalyst stories

Major readouts on the horizon for small developers | Evaluate

Biotech heads towards big catalysts | Evaluate

Key second-quarter clinical readouts for pharma | Evaluate

Industry trends

Share This Article